{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:10:49Z","timestamp":1788012649141,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.urolonc.2021.07.022","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T01:31:03Z","timestamp":1628904663000},"page":"764-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"given":"Ekaterina","family":"Laukhtina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Quhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Sari Motlagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Schuettfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Mostafaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico \u0421.","family":"Grossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Resch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Enikeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Schmidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.07.022_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","author":"Janzen","year":"2003","journal-title":"Urol Clin N Am"},{"issue":"4","key":"10.1016\/j.urolonc.2021.07.022_bib0002","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2019.04.007","article-title":"Adjuvant therapy for urothelial and renal cell carcinoma","author":"Patel","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2018.05.002","article-title":"Adjuvant vascular endothelial growth factor\u2013targeted therapy in renal cell carcinoma: a systematic review and pooled analysis [Figure presented]","author":"Sun","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2019.01.045","article-title":"Adjuvant therapy in high-risk renal cell cancer: a systematic review and meta-analysis","author":"Riaz","year":"2019","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2018.12.011","article-title":"Adjuvant tyrosine kinase inhibitors in treatment of renal cell carcinoma: a meta-analysis of available clinical trials","author":"Massari","year":"2019","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2018.01.003","article-title":"Adjuvant therapies in nonmetastatic renal-cell carcinoma: a review of the literature","author":"Bandini","year":"2018","journal-title":"Clin. Genitourin Cancer."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0008","doi-asserted-by":"crossref","DOI":"10.5489\/cuaj.5187","article-title":"Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: a comprehensive analysis of the literature and meta-analysis of randomized controlled trials","author":"Karakiewicz","year":"2018","journal-title":"Can. Urol. Assoc. J."},{"issue":"9","key":"10.1016\/j.urolonc.2021.07.022_bib0009","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.6004\/jnccn.2020.0043","article-title":"Kidney cancer, version 1.2021: Featured updates to the nccn guidelines","volume":"18","author":"Motzer","year":"2020","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0010","article-title":"Renal cell carcinoma EAU guidelines on renal cell carcinoma: 2020","author":"Ljungberg","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2017.09.008","article-title":"Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results","author":"Motzer","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0076","article-title":"Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial","author":"Haas","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0013","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01800","article-title":"Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: Results from the SORCE randomized phase III intergroup trial","author":"Eisen","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2021.07.022_bib0014","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0016","doi-asserted-by":"crossref","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. A generalised linear modelling framework for pairwise and network meta-analysis of randomized controlled trials. Medical Decision Making 2012, 33(5), 607\u2013617.","DOI":"10.1177\/0272989X12458724"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","author":"van Valkenhoef","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0018","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-10-54","article-title":"Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial","author":"Woods","year":"2010","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0020","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","author":"R\u00fccker","year":"2015","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","author":"Haas","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0022","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","author":"Ravaud","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","author":"Gross-Goupil","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma","author":"Motzer","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2021.07.022_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.5697","article-title":"The US food and drug administration's approval of adjuvant sunitinib for renal cell cancer: a case of regulatory capture?","author":"Gyawali","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2017.09.004","article-title":"Adjuvant therapy in renal cell carcinoma","author":"Massari","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0029","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2521081059","article-title":"Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?","author":"Schor-Bardach","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.urolonc.2021.07.022_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2017.04.092","article-title":"Adjuvant therapy for high risk localized kidney cancer: emerging evidence and future clinical trials","author":"Lenis","year":"2018","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:21:43Z","timestamp":1761042103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921003409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1078143921003409"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.022","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}